Table 3.

studies from literature dealing with the dosing regimens respectively used to achieve neuromuscular blockade and recovery time

Author, Year	Design	N	Objective	Dose of cisatracurium	Recovery time(min)* Recovery index**
Prielipp et al. [24] 1995	Prospective randomized double blind multicenter	28	Recovery time cisatracurium vs. vecuronium	Mean infusion 0.15mg.kg–1.h–1	68±13*
Boyd et al. [15] 1996	Prospective randomized clinical trial	6	PK-PD cistracurium vs. atracurium	Bolus 0.1mg.kg–1.h–1 mean infusion 0.19mg.kg–1.h–1	60 (20-85)*
Pearson et al. [23] 1996	Prospective randomized, single-blind study	12	Infusion requirement nd recovery of ciasatracurium vs. atracurium	Bolus 0.1mg.kg–1.h–1 Mean infusion 0.23mg.kg–1.h–1	46 (8.3-64)*
Lagneau et al. [18] 2002	Open labeled multicenter prospective randomized study	102	TOF 2/4 vs. 0/4 of continuous infusion of cisatracurium	Mean infusion 0.21mg.kg–1.h–1	-
Baumann et al. [22] 2004	Prospective randomized	30	TOF vs. clinical assessment	Mean infusion 2.3±0.2µg.kg–1.h–1	45±7*
Burmester et al. [28] 2005	Prospective randomized double-blind	37	Vecuronium vs. cisatracurium contiunuous infusion in children ICU	-	-
Forel et al. [29] 2006	Prospective multicenter randomized trial	36	NMBA on gas exchange	Bolus, 0.2mg.kg–1 continuous infusion at an initial rate of 5µg.kg–1.h–1	-
Papazian et al. [30] 2010	Multicenter double-blind trial	340	Clinical outcomes 2 days of NMBA in ARDS patients	-	-
Dong et al. [31] 2012	Prospective experimental	30	PD of cisatracurium continuous infusion vs. bolus injection	-	13.13±3.36**
Dieye et al. [12] 2014	Prospective observational study	34	Cisatracurium required doses in MICU vs. SICU	0.15mg/kg followed by repeated boluses of 0.03mg/kg every four minutes.	-
Diaz et al. [32] 2014	Prospective experimental	10	Potency, onset and recovery cisatracurium vs. CW002 and pancuronium	multiple intravenous doses starting at 0.015mg.kg–1	5.6±0.8**